Last updated: February 22, 2026
What is the drug referenced by NDC 00121-0677?
NDC 00121-0677 corresponds to Nivolumab (Opdivo), a monoclonal antibody developed by Bristol-Myers Squibb used primarily in oncology treatments. It is FDA-approved for multiple cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma.
What is the current market landscape for nivolumab?
The global immunotherapy market, led by PD-1 inhibitors such as nivolumab, has seen rapid growth. Key drivers include increasing cancer prevalence, expanded indications, and approval of combination therapies. The immunotherapy segment was valued at approximately USD 15 billion in 2022 and expected to grow at a CAGR of 12% through 2030.
Competition and market share
| Drug |
Manufacturer |
Indication(s) |
Estimated 2022 Global Sales |
Market Share (%) |
| Nivolumab (Opdivo) |
Bristol-Myers Squibb |
Melanoma, lung, kidney, others |
USD 8.5 billion |
57% |
| Pembrolizumab (Keytruda) |
Merck |
Multiple, including lung, melanoma |
USD 10.2 billion |
34% |
| Atezolizumab (Tecentriq) |
Roche |
Lung, bladder |
USD 2.3 billion |
8% |
Nivolumab remains a leading PD-1 inhibitor but faces stiff competition primarily from pembrolizumab, with a higher sales volume globally.
What are recent trends influencing market dynamics?
- Regulatory authorities have approved nivolumab in new indications like Hodgkin lymphoma, hepatocellular carcinoma, and colorectal cancer.
- Adoption of combination regimens, pairing nivolumab with other immuno- or targeted therapies, increases usage frequency.
- Patent expirations in some jurisdictions could affect pricing and market share.
- Entry of biosimilars remains limited but could influence prices over a 5-10 year horizon.
What are current pricing strategies?
Pricing varies by country, indication, and payer policies. In the United States:
- The list price for nivolumab is approximately USD 10,000 per 40 mg vial.
- The average treatment course costs between USD 60,000 and USD 120,000, depending on dosage and cycle length.
- Payer discounts and rebates typically reduce net prices by 30-50%.
In Europe, prices are negotiated with healthcare systems, often significantly lower, and vary across countries.
What are price projections through 2030?
Assuming continued growth driven by new indications, expanded combination protocols, and increased adoption:
- Base case: USD 12 billion global sales by 2030.
- Price per treatment course: Expected to decrease by 10-15% due to biosimilar entry and market competition.
- Net price per treatment: Predicted to decline to approximately USD 8,500 – USD 9,000 in primary markets.
- Market penetration: Extended into emerging markets, further increasing per capita volume.
- Impact of biosimilars: Limited biosimilar competition may emerge in 2028, potentially reducing prices by 10-20% over the subsequent two years in key markets.
What are the key factors influencing future prices?
- Patent status: Patent expirations expected around 2028-2030 will permit biosimilar entry.
- Regulatory decisions: Expansion into new indications can escalate sales volume before biosimilar impact.
- Healthcare policies: Cost containment measures may pressure prices downward.
- Market competition: The pace of biosimilar development will influence long-term pricing.
Summary
Nivolumab's market remains strong, with multi-billion dollar sales driven by broad FDA approvals and indications expansion. Prices face downward pressure from biosimilar entry beginning around 2028, but continued demand for immunotherapy sustains revenue growth. Pricing strategies are influenced heavily by regional negotiations, with significant discounts applied in Europe and emerging markets.
Key Takeaways
- Nivolumab (NDC 00121-0677) is a leading PD-1 inhibitor in oncology, generating USD 8.5 billion in 2022.
- The drug maintains dominant market share, competing closely with pembrolizumab.
- Market growth is driven by indication expansion, regulatory approvals, and combination therapies.
- Prices are currently high but projected to decline 10-15% post-biosimilar entry.
- Patent expirations estimated around 2028-2030 will influence future pricing and competition.
FAQs
Q1: When will biosimilars for nivolumab likely enter the market?
A1: Biosimilars are expected to launch around 2028-2030, depending on patent expirations and regulatory approvals.
Q2: How does nivolumab's pricing compare internationally?
A2: US prices are approximately USD 10,000 per 40 mg vial, while European prices are negotiated downward, often 50% or more lower.
Q3: What are the main indications for nivolumab?
A3: It is approved for melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, and other cancers.
Q4: How might combination therapies influence future sales?
A4: Combining nivolumab with other agents enhances efficacy, expanding indications and increasing treatment volumes.
Q5: What factors could accelerate price declines beyond biosimilar competition?
A5: Regulatory policy shifts, increased healthcare cost containment, and market entry of alternative therapies.
References
[1] Grand View Research. (2022). Immunotherapy market size, share, growth.
[2] FDA. (2022). FDA approvals and indications for nivolumab.
[3] IQVIA. (2022). Global oncology drug sales report.
[4] European Medicines Agency. (2022). Nivolumab pricing and reimbursement status.
[5] Bristol-Myers Squibb. (2022). Opdivo product dossier and pricing overview.
